Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but the problem of low response rates remains. At the ASCO an
Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.
Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but has not yet become hormone resistant, stepping up pressure on rival therapy Zytiga from Johnson
Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two
Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.